Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4290-4294

  King, Jennifer R ^a   Yogev, Ram ^b   Jean Philippe, Patrick ^c   Graham, Bobbie ^d   Wiznia, Andrew ^e   Britto, Paula ^f   Carey, Vincent ^f   Hazra, Rohan ^g   Acosta, Edward P ^a  

^a University of Alabama at Birmingham   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e JACOBI MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; TENOFOVIR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; BENZOXAZINES; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES; RITONAVIR;

EID: 80051813706     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01334-10     Document Type: Article

References (17)

1. Agarwala, S., et al. 2005. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects, abstr. 16. Sixth Int. Workshop Clin. Pharmacol. HIV Ther. Quebec City, Quebec, Canada, 26 to 29 April 2005.
2. Droste, J A, B P Kearney, Y A Hekster, and D M Burger. 2006. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 41:37-43. (Pubitemid 41786017)
3. Gallant, J E, et al. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trail. JAMA 292:191-201. (Pubitemid 38917996)
4. Gilead Sciences and Bristol-Myers Squibb. 2010. Atripla, product information. Gilead Sciences Inc., Foster City, CA, and Bristol-Myers Squibb, Princeton, NJ.
5. Gilead Sciences. 2009. Truvada, product information, Gilead Sciences Inc., Foster City, CA.
6. Gilead Sciences. 2009. Viread, product information, Gilead Sciences Inc., Foster City, CA.
7. Hazra, R., et al. 2004. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob. Agents Chemother. 48:124-129. (Pubitemid 38040187)
8. Hoetelmans, R M, et al. 2007. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br. J. Clin. Pharmacol. 64:655-661. (Pubitemid 47568821)
9. Kiser, J J, et al. 2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimcirob. Agents Chemother. 52:631-637. (Pubitemid 351170838)
10. Kiser, J J, et al. 2005. Pharmacokinetics of atazanavir/ritonavir in HIV-infected infants, children, and adolescents: PACTG 1020, abstr. 767. Twelfth Conf. Retrovir. Opportunistic Infect., Boston, MA, 22 to 25 February 2005.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009; 1-161, Table 5a. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 15 May 2010.
12. Sekar, V., et al. 2006. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC 114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV infected patients, abstr. 639b. Thirteenth Conf. Retrovir. Opportunistic Infect., Denver, CO, 2 to 5 February 2006.
13. Squires, K., et al. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann. Intern. Med. 139:313-320.
14. Starr, S E, et al. 1999. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N. Engl. J. Med. 341:1874-1881.
15. Szczech, L A 2008. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top. HIV Med. 6:122-126.
16. Taburet, A M, et al. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096.
17. Tong, L., et al. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51:3498-3504. (Pubitemid 47519335)